News

Lexaria Bioscience Corp.: Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study
DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus®DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus®DehydraTECH-GLP-1 s ...
Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study
Detailed price information for Lexaria Bioscience Corp WT (LEXXW-Q) from The Globe and Mail including charting and trades.
Veru to Participate in the 2025 BTIG Virtual Biotech Conference
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the ...
Endocrinology Advisor17d
Tirzepatide Superior to Semaglutide in T2D Therapy Targets
Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.